News
FDA, Sarepta and Elevidys
Digest more
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the ...
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
6don MSN
Sarepta Therapeutics' (SRPT) stock continued to sink Tuesday, down more than 4% in pre-market trade, following a rough end to ...
2d
Investor's Business Daily on MSNSarepta Therapeutics' Brutal Week Continues With Bad News Out Of EuropeSarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results